11位分析师将AnaptysBio评为"中等购买", 平均12个月的目标价格为50.30美元. 11 analysts rate AnaptysBio a "Moderate Buy" with an average 12-month price target of $50.30.

临床阶段生物技术公司AnaptysBio获得了来自11位分析师的"适度购买"评级,平均12个月的目标价格为50.30美元. AnaptysBio, a clinical-stage biotech firm, has received a consensus "Moderate Buy" rating from 11 analysts covering the company, with an average 12-month price target of $50.30. 尽管缺少Q2收入估计数,但该公司看到各种分析家提出的价格目标不断提高,包括Truist Finance 30美元、Jp摩根大通75美元和HC Wainwright 55美元。 Despite missing Q2 earnings estimates, the firm has seen increasing price targets from various analysts, including Truist Financial at $30, JPMorgan Chase at $75, and HC Wainwright at $55. 内部活动也值得注意,主要股东Ecor1购买了273 972股股票,平均价格为36.50美元。 Insider activity has also been noteworthy, with major shareholder Ecor1 Capital purchasing 273,972 shares at an average price of $36.50.